Related Experiment Videos
Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?
1Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain. xmontal@hg.vhebron.es
Journal of Neurology
|June 3, 2000
Summary
Interferon-beta1b for multiple sclerosis can cause flu-like symptoms. Patients experiencing fever often show higher interleukin-6 levels, suggesting a link between this cytokine and treatment side effects.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Relapsing-remitting multiple sclerosis (RRMS) is an autoimmune condition affecting the central nervous system.
- Interferon-beta1b is a common therapeutic agent for RRMS, but frequently causes systemic side effects like fever and flu-like symptoms.
Purpose of the Study:
- To investigate the potential biomarker for predicting fever side effects in patients undergoing interferon-beta1b treatment for RRMS.
- To explore the role of specific cytokines in mediating treatment-induced fever.
Main Methods:
- Peripheral blood leukocytes from RRMS patients were stimulated in vitro with interferon-beta1b prior to therapy initiation.
- Interleukin-6 levels were measured in patients who subsequently developed fever compared to those who did not.
Main Results:
- Patients who developed fever after starting interferon-beta1b treatment exhibited significantly higher levels of interleukin-6.
- Elevated baseline interleukin-6 may indicate a predisposition to experiencing fever as a side effect.
Conclusions:
- Interleukin-6 may play a role in the pathogenesis of interferon-beta1b-induced fever in RRMS patients.
- Measuring interleukin-6 levels before treatment could potentially help predict patients at higher risk for fever side effects.